A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
Price : $35 *
At a glance
- Drugs Domagrozumab (Primary) ; Domagrozumab (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 12 Mar 2016 Population pharmacokinetic/pharmacodynamic model results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.